Cargando…
Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity
BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1α,20-dihydroxyvitamin D3 (1,20(OH)(2)D3). It also cleaves the side chain of 7-dehydrocholesterol producing 7-dehydropregnenolone (7DHP), which can be transf...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845617/ https://www.ncbi.nlm.nih.gov/pubmed/20360850 http://dx.doi.org/10.1371/journal.pone.0009907 |
_version_ | 1782179420192112640 |
---|---|
author | Slominski, Andrzej T. Janjetovic, Zorica Fuller, Brian E. Zmijewski, Michal A. Tuckey, Robert C. Nguyen, Minh N. Sweatman, Trevor Li, Wei Zjawiony, Jordan Miller, Duane Chen, Tai C. Lozanski, Gerard Holick, Michael F. |
author_facet | Slominski, Andrzej T. Janjetovic, Zorica Fuller, Brian E. Zmijewski, Michal A. Tuckey, Robert C. Nguyen, Minh N. Sweatman, Trevor Li, Wei Zjawiony, Jordan Miller, Duane Chen, Tai C. Lozanski, Gerard Holick, Michael F. |
author_sort | Slominski, Andrzej T. |
collection | PubMed |
description | BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1α,20-dihydroxyvitamin D3 (1,20(OH)(2)D3). It also cleaves the side chain of 7-dehydrocholesterol producing 7-dehydropregnenolone (7DHP), which can be transformed to 20(OH)7DHP. UVB induces transformation of the steroidal 5,7-dienes to pregnacalciferol (pD) and a lumisterol-like compounds (pL). METHODS AND FINDINGS: To define the biological significance of these P450scc-initiated pathways, we tested the effects of their 5,7-diene precursors and secosteroidal products on leukemia cell differentiation and proliferation in comparison to 1α,25-dihydroxyvitamin D3 (1,25(OH)(2)D3). These secosteroids inhibited proliferation and induced erythroid differentiation of K562 human chronic myeloid and MEL mouse leukemia cells with 20(OH)D3 and 20,23(OH)(2)D3 being either equipotent or slightly less potent than 1,25(OH)(2)D3, while 1,20(OH)(2)D3, pD and pL compounds were slightly or moderately less potent. The compounds also inhibited proliferation and induced monocytic differentiation of HL-60 promyelocytic and U937 promonocytic human leukemia cells. Among them 1,25(OH)(2)D3 was the most potent, 20(OH)D3, 20,23(OH)(2)D3 and 1,20(OH)(2)D3 were less active, and pD and pL compounds were the least potent. Since it had been previously proven that secosteroids without the side chain (pD) have no effect on systemic calcium levels we performed additional testing in rats and found that 20(OH)D3 had no calcemic activity at concentration as high as 1 µg/kg, whereas, 1,20(OH)(2)D3 was slightly to moderately calcemic and 1,25(OH)(2)D3 had strong calcemic activity. CONCLUSIONS: We identified novel secosteroids that are excellent candidates for anti-leukemia therapy with 20(OH)D3 deserving special attention because of its relatively high potency and lack of calcemic activity. |
format | Text |
id | pubmed-2845617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-28456172010-04-02 Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity Slominski, Andrzej T. Janjetovic, Zorica Fuller, Brian E. Zmijewski, Michal A. Tuckey, Robert C. Nguyen, Minh N. Sweatman, Trevor Li, Wei Zjawiony, Jordan Miller, Duane Chen, Tai C. Lozanski, Gerard Holick, Michael F. PLoS One Research Article BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1α,20-dihydroxyvitamin D3 (1,20(OH)(2)D3). It also cleaves the side chain of 7-dehydrocholesterol producing 7-dehydropregnenolone (7DHP), which can be transformed to 20(OH)7DHP. UVB induces transformation of the steroidal 5,7-dienes to pregnacalciferol (pD) and a lumisterol-like compounds (pL). METHODS AND FINDINGS: To define the biological significance of these P450scc-initiated pathways, we tested the effects of their 5,7-diene precursors and secosteroidal products on leukemia cell differentiation and proliferation in comparison to 1α,25-dihydroxyvitamin D3 (1,25(OH)(2)D3). These secosteroids inhibited proliferation and induced erythroid differentiation of K562 human chronic myeloid and MEL mouse leukemia cells with 20(OH)D3 and 20,23(OH)(2)D3 being either equipotent or slightly less potent than 1,25(OH)(2)D3, while 1,20(OH)(2)D3, pD and pL compounds were slightly or moderately less potent. The compounds also inhibited proliferation and induced monocytic differentiation of HL-60 promyelocytic and U937 promonocytic human leukemia cells. Among them 1,25(OH)(2)D3 was the most potent, 20(OH)D3, 20,23(OH)(2)D3 and 1,20(OH)(2)D3 were less active, and pD and pL compounds were the least potent. Since it had been previously proven that secosteroids without the side chain (pD) have no effect on systemic calcium levels we performed additional testing in rats and found that 20(OH)D3 had no calcemic activity at concentration as high as 1 µg/kg, whereas, 1,20(OH)(2)D3 was slightly to moderately calcemic and 1,25(OH)(2)D3 had strong calcemic activity. CONCLUSIONS: We identified novel secosteroids that are excellent candidates for anti-leukemia therapy with 20(OH)D3 deserving special attention because of its relatively high potency and lack of calcemic activity. Public Library of Science 2010-03-26 /pmc/articles/PMC2845617/ /pubmed/20360850 http://dx.doi.org/10.1371/journal.pone.0009907 Text en Slominski et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Slominski, Andrzej T. Janjetovic, Zorica Fuller, Brian E. Zmijewski, Michal A. Tuckey, Robert C. Nguyen, Minh N. Sweatman, Trevor Li, Wei Zjawiony, Jordan Miller, Duane Chen, Tai C. Lozanski, Gerard Holick, Michael F. Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity |
title | Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity |
title_full | Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity |
title_fullStr | Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity |
title_full_unstemmed | Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity |
title_short | Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity |
title_sort | products of vitamin d3 or 7-dehydrocholesterol metabolism by cytochrome p450scc show anti-leukemia effects, having low or absent calcemic activity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845617/ https://www.ncbi.nlm.nih.gov/pubmed/20360850 http://dx.doi.org/10.1371/journal.pone.0009907 |
work_keys_str_mv | AT slominskiandrzejt productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT janjetoviczorica productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT fullerbriane productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT zmijewskimichala productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT tuckeyrobertc productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT nguyenminhn productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT sweatmantrevor productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT liwei productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT zjawionyjordan productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT millerduane productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT chentaic productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT lozanskigerard productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity AT holickmichaelf productsofvitamind3or7dehydrocholesterolmetabolismbycytochromep450sccshowantileukemiaeffectshavingloworabsentcalcemicactivity |